Status:
COMPLETED
Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis
Lead Sponsor:
Bayer
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the safety and efficacy of three concentrations of ZK 245186 ointment and vehicle on increasing body surface areas for the treatment of atopic dermatitis and ...
Eligibility Criteria
Inclusion
- diagnosis of atopic dermatitis (Hanifin and Rajka criteria)
- mild to moderate atopic dermatitis at beginning of study
- wash-out periods for systemic and topical treatments for atopic dermatitis
- females must use effective contraception
Exclusion
- pregnant or lactating women
- conditions that in the opinion of the investigator may pose a risk or interfere with the evaluation of the study
- wide-spread atopic dermatitis requiring systemic treatment
- diagnosed with immunocompromised status
- skin diseases - other than atopic dermatitis - in the treatment area
- mental handicap or legally incompetent
Key Trial Info
Start Date :
July 15 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 15 2010
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00944632
Start Date
July 15 2009
End Date
September 15 2010
Last Update
June 7 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
PAREXEL International (Bloemfontein)
Bloemfontein, South Africa, 9301
2
PAREXEL International (George)
George, South Africa, 6529
3
PAREXEL International (Port Elizabeth)
Newton Park, South Africa, 6045